E1A binding protein p400Genealiases: CAGH32 · P400 · TNRC12
Q-omics provides the consensus-scored EP400 profile across patient tissues and cancer cell-line models. EP400 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EP400 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, EP400 RNA expression shows 21,460 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where EP400 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EP400 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EP400 survival associations across molecular data types. EP400 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EP400 RNA expression–survival associations across cancer types. High EP400 expression shows unfavorable associations in ACC, MESO, LIHC and KICH, but favorable associations in SCLC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EP400 RNA expression.
This table summarizes EP400 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EP400. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EP400 shows higher tumor expression in LIHC, COAD, HNSC, KIRP, CHOL and BLCA. The LIHC box plot shows higher EP400 RNA expression in tumor versus normal tissue (log2 FC = +1.089, t-test p < 0.001).
This table shows molecular features associated with EP400 in patient tissues and cancer cell lines. In patient samples, EP400 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EP400 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
